Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bushimatsu and Keishikajutsubuto for prevention of oxaliplatin-induced peripheral neuropathy in colorectal cancer
jRCTs051180101Phase 2Completed
- Start
- Jan 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of keishikajutsubuto in colorectal cancer (CRC) and chemotherapy-induced peripheral neuropathy (CIPN). Primary endpoints: Dose-limiting toxicity of Bushimatsu, Maximum tolerated dose of Bushimatsu and 1 more. Started Jan 2018; status: completed.
02
Drugs
keishikajutsubuto
03
Conditions
colorectal cancer (CRC)chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCTs051180101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180101.